Evidence Hub

Combination therapy of essential hypertension with pindolol (Visken) and hydralazine

Persson I

Advances in clinical pharmacology, 1976

Abstract

Thirty patients suffering from essential hypertension were treated successively with placebo, hydralazine alone, and pindolol (Viskén) combined with hydralazine. As compared to placebo hydralazine brought about a statistically significant reduction in blood pressure and an increase in pulse rate; palpitation was an irritating side-effect. Combining hydralazine and pindolol caused an additional fall in blood pressure (2 p less than 0.001) and the pulse rate decreased (2 p less than 0.001). This combination treatment had a favourable effect on the palpitation and angina pectoris also.

How strong is the evidence?

Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free